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Clinics 
Age and sex: 67 years old male patient. 
Previous History : no preleukemia; no previous 
malignant disease; no inborn condition of note. 
Organomegaly : no hepatomegaly ; no splenomegaly ; 
no enlarged lymph nodes ; no central nervous system 
involvement. 
Blood 
WBC: 3,6 x 109/l; Hb: 8,6 g/dl; platelets: 151x 109/l; 
blasts: 56%. 
Bone marrow: Cellularity fewer than usual. Rare 
megakaryocytes, presence of micromegakaryocytes. 
Infiltration by blasts at a level of 58% with myeloid 
features. Dysgranulopoiesis >10 % of non erythoblastic 
cells. 
Cytopathology classification 
Immunophenotype: CD34 (85%), HLA DR (91%) and 
myeloid cluster: CD11c (7%), CD13 (97%), CD13c 
(99%), CD33 (98%), CD117 (81%), MPO 5% and only 
one lymphoid cluster CD7 (87%). Conclusion: 
immature myeloid population. Phenotype FAB M0. 
Rearranged Ig or Tcr: Not done. 
Pathology: Secondary Acute Respiratory desease due to 
a bilateral alveolar pneumopathy on June 2005, without 
suitable microbiological data, following an aplasia 
phase with fever at D+16 (chemotherapy induction 
step). 
Electron microscopy: No. 
Precise diagnosis: AML type Mo with myelodysplasia. 
Survival 
Date of diagnosis: 04-2005. 
Treatment: LAM SA 2002 Protocol. Idarubicine: 15mg  
per day from J1 to J5 / Aracytine: 180 mg per day from 
J1 to J7 / Belustine: 360 mg only at J1 then Aracytine 
and Idarubicine each three month during 15 days (6 
cures). 
Complete remission: Yes during induction phase. 
Treatment related death: No. 
Relapse: No. 
Status: Alive 08-2005. 
Survival: 5 months. 
Karyotype 
Sample: Bone marrow; Culture time: 24/48h; Banding: 
R. 
Results: 46, XY, t(4;12)(q11;p13.1) [27] / 46, XY [3] 





No AML/ETO t(8;21)(q22;q22) translocation, no split 
of MLL performed by FISH analysis. 
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